CurrentColorado Rocky Mountain Health PlansPolicy N/A

Myalept (metreleptin) — Prior Authorization / Medical Necessity

Defines prior authorization and medical necessity criteria for Myalept (metreleptin) therapy for patients with congenital or acquired generalized lipodystrophy; applies to prescribers and payers administering UnitedHealthcare Pharmacy Clinical Pharmacy Programs.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyMyalept (metreleptin) — Prior Authorization / Medical Necessity

Policy CodePolicy N/A

Change TypeNo material clinical changes

Effective DateSep 1, 2025

Next Review DateJun 1, 2025

Key ActionObtain prior authorization and document diagnosis of congenital or acquired generalized lipodystrophy with required metabolic criteria and endocrinologist prescription.

SourceLink

12 monthsauth duration

>7.0A1C threshold

>200TG threshold (mg/dL)

Endocrinologistprescriber

RequiredREMS

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Authorization

Covered when ALL of the following are met:

Metabolic criteria: Either (1) diabetes mellitus or insulin resistance with persistent hyperglycemia (HgbA1C > 7.0) despite dietary intervention AND optimized insulin therapy at maximum tolerated doses OR (2) persistent hypertriglyceridemia (TG > 200 mg/dL) despite dietary intervention AND optimized therapy with at least two triglyceride-lowering agents from different classes at maximum tolerated doses.HgbA1C > 7.0; TG > 200 mg/dL

Reauthorization

Covered when ALL of the following are met:

Reauthorization: Documentation of positive clinical response to Myalept therapy; Myalept continues as an adjunct to diet modification; prescribed by an endocrinologist.

Authorization issued for 12 months

Use of Myalept (metreleptin) is limited to patients with generalized lipodystrophy; the safety and effectiveness have not been established for partial lipodystrophy. Myalept is not indicated for patients with HIV-related lipodystrophy or for treatment of liver disease, including NASH. The agent is also not indicated for patients with metabolic disease in the absence of documented generalized lipodystrophy. Additionally, Myalept is available only through a restricted distribution program under a REMS due to risks related to anti-metreleptin neutralizing antibodies and lymphoma.

Key Clinical Thresholds and Codes

HgbA1C threshold

HgbA1C threshold for approval> 7.0

Context for thresholdPersistent hyperglycemia despite dietary intervention and optimized insulin therapy at maximum tolerated doses

Authorization duration when threshold metApproval issued for 12 months

Triglycerides threshold

Triglycerides threshold for approval (mg/dL)> 200 mg/dL

Context for thresholdPersistent hypertriglyceridemia despite dietary intervention and optimized therapy with at least two triglyceride-lowering agents from different classes at maximum tolerated doses

Authorization duration when threshold metApproval issued for 12 months

Prescriber Requirements and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for Myalept (metreleptin). Initial approvals are issued for 12 months and require documentation of diagnosis, prescriber specialty, use as an adjunct to diet modification, and meeting either the hyperglycemia or hypertriglyceridemia pathway criteria. REMS is not specified in this policy; include REMS documentation if applicable per product labeling.

Affected product: Myalept (metreleptin)
Initial authorization duration: 12 months
Prescriber specialty required: Endocrinologist

Step Therapy

Step Therapy for Hypertriglyceridemia

For members with hypertriglyceridemia, step therapy is required prior to approval. The member must have tried and not responded adequately to dietary intervention plus at least two triglyceride-lowering agents from different classes at maximum tolerated doses (examples: fibrates, statins).

Trigger: Persistent hypertriglyceridemia (TG > 200)
Required trials: Dietary intervention; at least two triglyceride-lowering agents from different classes (e.g., fibrate, statin) at maximum tolerated doses

Documentation Required

Reauthorization Documentation Required

Reauthorization requires documentation of ongoing clinical benefit and continued use as an adjunct to diet modification, and the prescription must continue to be managed by an endocrinologist. Provide clinical notes showing positive response to therapy.

Evidence of positive clinical response (e.g., improved HgbA1C, reduced triglycerides, or other clinically relevant measures)
Confirmation that Myalept remains adjunctive to diet modification
Current prescribing endocrinologist information

Denial Risk

Denial Risk for Unmet Criteria

Requests that do not meet the specified initial or reauthorization criteria (diagnosis, prescriber specialty, adjunctive diet use, required prior treatments for hypertriglyceridemia, or documentation of clinical response on reauthorization) are at high risk for denial. Automated approvals based solely on claim history may occur in some programs.

High denial risk if: diagnosis is not congenital/acquired generalized lipodystrophy associated with leptin deficiency
High denial risk if not prescribed by an endocrinologist or if diet adjunctive use is not documented
High denial risk for TG pathway without dietary trial and ≥2 triglyceride-lowering agents
Note: previous claim/medication history or automated processes may override in certain programs

Key Definitions

Generalized lipodystrophy

DefinitionGeneralized lipodystrophy: a form of lipodystrophy (congenital or acquired) associated with leptin deficiency for which metreleptin (Myalept) is indicated.

Distinction from partial formsSafety and effectiveness of Myalept for partial lipodystrophy have not been established; partial lipodystrophy is excluded from indication.

Related contraindications/limitsMyalept is not indicated for HIV-related lipodystrophy or metabolic disease without generalized lipodystrophy; also not established for liver disease including NASH.

Relation to metreleptin indicationMetreleptin is indicated as adjunctive replacement therapy to treat complications of leptin deficiency in congenital or acquired generalized lipodystrophy and is available only through a REMS program.